Literature DB >> 11641434

Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives.

Z G Gao1, J E Van Muijlwijk-Koezen, A Chen, C E Müller, A P Ijzerman, K A Jacobson.   

Abstract

Allosteric modulators of A(1) and A(2A) adenosine receptors have been described; however, for the A(3) adenosine receptor, neither an allosteric site nor a compound with allosteric effects has been described. In this study, the allosteric modulation of human A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives was investigated by examining their effects on the dissociation of the agonist radioligand, [(125)I]N(6)-(4-amino-3-iodobenzyl)-5'-N-methylcarboxamidoadenosine (I-AB-MECA), from the receptor. Several 3-(2-pyridinyl)isoquinoline derivatives, including VUF5455, VUF8502, VUF8504, and VUF8507, slowed the dissociation of the agonist radioligand [(125)I]I-AB-MECA in a concentration-dependent manner, suggesting an allosteric interaction. These compounds had no effect on the dissociation of the radiolabeled antagonist [(3)H]PSB-11 from the A(3) adenosine receptor, suggesting a selective enhancement of agonist binding. By comparison, compounds of similar structure (VUF8501, VUF8503, VUF8505), the classical adenosine receptor antagonist CGS15943 and the A(1) receptor allosteric enhancer PD81723 did not significantly influence the dissociation rate of [(125)I]I-AB-MECA. The effect of agonist on forskolin-induced cAMP production was significantly enhanced by VUF5455. When the subtype-selectivity of the allosteric enhancement was tested the compounds had no effect on the dissociation of either [(3)H]N(6)-[(R)-phenylisopropyl]adenosine from the A(1) adenosine receptor or [(3)H]CGS21680 from the A(2A) adenosine receptor. Probing of structure-activity relationships suggested that a carbonyl group is essential for allosterism but preferred only for competitive antagonism. The presence of a 7-methyl group decreased the competitive binding affinity without a major loss of the allosteric enhancing activity, suggesting that the structural requirements for allosteric enhancement might be distinct from those for competitive antagonism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11641434      PMCID: PMC3953614     

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  35 in total

Review 1.  Allosteric activation of the CaR by L-amino acids.

Authors:  B Kobilka
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

Review 2.  Structure and function of adenosine receptors and their genes.

Authors:  B B Fredholm; G Arslan; L Halldner; B Kull; G Schulte; W Wasserman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-11       Impact factor: 3.000

3.  Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide.

Authors:  E A Thomas; M J Carson; M J Neal; J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

4.  Direct preconditioning of cultured chick ventricular myocytes. Novel functions of cardiac adenosine A2a and A3 receptors.

Authors:  J Strickler; K A Jacobson; B T Liang
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

5.  CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding.

Authors:  S Litschig; F Gasparini; D Rueegg; N Stoehr; P J Flor; I Vranesic; L Prézeau; J P Pin; C Thomsen; R Kuhn
Journal:  Mol Pharmacol       Date:  1999-03       Impact factor: 4.436

6.  In vitro characterization of tachykinin NK2-receptors modulating motor responses of human colonic muscle strips.

Authors:  T Croci; G Aureggi; L Manara; X Emonds-Alt; G Le Fur; J P Maffrand; S Mukenge; G Ferla
Journal:  Br J Pharmacol       Date:  1998-07       Impact factor: 8.739

7.  Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor.

Authors:  Q Y Zhou; C Li; M E Olah; R A Johnson; G L Stiles; O Civelli
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

8.  Identification of a [3H]Ligand for the common allosteric site of muscarinic acetylcholine M2 receptors.

Authors:  C Tränkle; E Mies-Klomfass; M H Cid; U Holzgrabe; K Mohr
Journal:  Mol Pharmacol       Date:  1998-07       Impact factor: 4.436

9.  A role for mast cells in adenosine A3 receptor-mediated hypotension in the rat.

Authors:  J P Hannon; H J Pfannkuche; J R Fozard
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

Review 10.  A(3) adenosine receptor antagonists.

Authors:  C E Müller
Journal:  Mini Rev Med Chem       Date:  2001-11       Impact factor: 3.862

View more
  27 in total

1.  Chapter 13. A3 Adenosine Receptors.

Authors:  Kenneth A Jacobson; Susanna Tchilibon; Bhalchandra V Joshi; Zhan-Guo Gao
Journal:  Annu Rep Med Chem       Date:  2003       Impact factor: 1.059

2.  The allosteric enhancer PD81,723 increases chimaeric A1/A2A adenosine receptor coupling with Gs.

Authors:  Samita Bhattacharya; Rebecca L Youkey; Kobina Ghartey; Matthew Leonard; Joel Linden; Amy L Tucker
Journal:  Biochem J       Date:  2006-05-15       Impact factor: 3.857

3.  Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor.

Authors:  Anikó Göblyös; Zhan-Guo Gao; Johannes Brussee; Roberto Connestari; Sabrina Neves Santiago; Kai Ye; Adriaan P Ijzerman; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2006-06-01       Impact factor: 7.446

4.  Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A₃ adenosine receptor.

Authors:  Lili Du; Zhan-Guo Gao; Kasem Nithipatikom; Adriaan P Ijzerman; Jacobus P D van Veldhoven; Kenneth A Jacobson; Garrett J Gross; John A Auchampach
Journal:  J Pharmacol Exp Ther       Date:  2011-10-19       Impact factor: 4.030

Review 5.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

6.  Effects of the allosteric modulator SCH-202676 on adenosine and P2Y receptors.

Authors:  Zhan-Guo Gao; Ariel S Gross; Kenneth A Jacobson
Journal:  Life Sci       Date:  2004-05-07       Impact factor: 5.037

7.  Antagonist selective modulation of adenosine A1 and A3 receptor pharmacology by the food dye Brilliant Black BN: evidence for allosteric interactions.

Authors:  L T May; S J Briddon; S J Hill
Journal:  Mol Pharmacol       Date:  2010-01-19       Impact factor: 4.436

8.  Adenosine and the auditory system.

Authors:  Srdjan M Vlajkovic; Gary D Housley; Peter R Thorne
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

9.  Novel 2- and 4-substituted 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric modulators of the A3 adenosine receptor.

Authors:  Yoonkyung Kim; Sonia de Castro; Zhan-Guo Gao; Adriaan P Ijzerman; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

10.  Allosteric modulation of adenosine receptors.

Authors:  Anikó Göblyös; Ad P Ijzerman
Journal:  Purinergic Signal       Date:  2008-07-10       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.